193 related articles for article (PubMed ID: 36827893)
1. Metformin-containing hydrogel scaffold to augment CAR-T therapy against post-surgical solid tumors.
Chao Y; Wei T; Li Q; Liu B; Hao Y; Chen M; Wu Y; Song F; Chen Q; Liu Z
Biomaterials; 2023 Apr; 295():122052. PubMed ID: 36827893
[TBL] [Abstract][Full Text] [Related]
2. Self-delivery of TIGIT-blocking scFv enhances CAR-T immunotherapy in solid tumors.
Yang F; Zhang F; Ji F; Chen J; Li J; Chen Z; Hu Z; Guo Z
Front Immunol; 2023; 14():1175920. PubMed ID: 37359558
[TBL] [Abstract][Full Text] [Related]
3. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
Miao L; Zhang Z; Ren Z; Tang F; Li Y
Front Immunol; 2021; 12():687822. PubMed ID: 34093592
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
5. A Near-Infrared-II Fluorescent Nanocatalyst for Enhanced CAR T Cell Therapy against Solid Tumor by Immune Reprogramming.
Li H; Yang X; Wang Z; She W; Liu Y; Huang L; Jiang P
ACS Nano; 2023 Jun; 17(12):11749-11763. PubMed ID: 37319120
[TBL] [Abstract][Full Text] [Related]
6. Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors.
Chen J; Jiang H
Crit Rev Immunol; 2021; 41(1):1-12. PubMed ID: 33822521
[TBL] [Abstract][Full Text] [Related]
7. Injectable and photocurable CAR-T cell formulation enhances the anti-tumor activity to melanoma in mice.
Zhou W; Lei S; Liu M; Li D; Huang Y; Hu X; Yang J; Li J; Fu M; Zhang M; Wang F; Li J; Men K; Wang W
Biomaterials; 2022 Dec; 291():121872. PubMed ID: 36323072
[TBL] [Abstract][Full Text] [Related]
8. Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors.
Akbari P; Katsarou A; Daghighian R; van Mil LWHG; Huijbers EJM; Griffioen AW; van Beijnum JR
Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188701. PubMed ID: 35202772
[TBL] [Abstract][Full Text] [Related]
9. Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor.
Zuo YH; Zhao XP; Fan XX
Pharmacol Res; 2022 Oct; 184():106454. PubMed ID: 36115525
[TBL] [Abstract][Full Text] [Related]
10. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
[TBL] [Abstract][Full Text] [Related]
12. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
13. Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors.
Grosskopf AK; Labanieh L; Klysz DD; Roth GA; Xu P; Adebowale O; Gale EC; Jons CK; Klich JH; Yan J; Maikawa CL; Correa S; Ou BS; d'Aquino AI; Cochran JR; Chaudhuri O; Mackall CL; Appel EA
Sci Adv; 2022 Apr; 8(14):eabn8264. PubMed ID: 35394838
[TBL] [Abstract][Full Text] [Related]
14. Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors.
Ghahri-Saremi N; Akbari B; Soltantoyeh T; Hadjati J; Ghassemi S; Mirzaei HR
Front Immunol; 2021; 12():738456. PubMed ID: 34721401
[TBL] [Abstract][Full Text] [Related]
15. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
Guedan S; Alemany R
Front Immunol; 2018; 9():2460. PubMed ID: 30405639
[TBL] [Abstract][Full Text] [Related]
16. Hurdles to breakthrough in CAR T cell therapy of solid tumors.
Marofi F; Achmad H; Bokov D; Abdelbasset WK; Alsadoon Z; Chupradit S; Suksatan W; Shariatzadeh S; Hasanpoor Z; Yazdanifar M; Shomali N; Khiavi FM
Stem Cell Res Ther; 2022 Apr; 13(1):140. PubMed ID: 35365241
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor T cells applied to solid tumors.
Zhou Z; Tao C; Li J; Tang JC; Chan AS; Zhou Y
Front Immunol; 2022; 13():984864. PubMed ID: 36389701
[TBL] [Abstract][Full Text] [Related]
18. Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance.
Qin Y; Xu G
Front Immunol; 2022; 13():1053120. PubMed ID: 36569859
[TBL] [Abstract][Full Text] [Related]
19. Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses.
Yang Y; McCloskey JE; Yang H; Puc J; Alcaina Y; Vedvyas Y; Gomez Gallegos AA; Ortiz-Sánchez E; de Stanchina E; Min IM; von Hofe E; Jin MM
Cancer Immunol Res; 2021 Oct; 9(10):1158-1174. PubMed ID: 34341066
[TBL] [Abstract][Full Text] [Related]
20. Engineering chimeric antigen receptor-T cells for cancer treatment.
Ye B; Stary CM; Li X; Gao Q; Kang C; Xiong X
Mol Cancer; 2018 Feb; 17(1):32. PubMed ID: 29448937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
